Correlation analysis of obesity phenotypes with leptin and adiponectin.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 10 2023
18 10 2023
Historique:
received:
19
04
2023
accepted:
25
09
2023
medline:
23
10
2023
pubmed:
19
10
2023
entrez:
18
10
2023
Statut:
epublish
Résumé
Obesity can be categorized as metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO). However, individuals with MHO are characterized by the absence of metabolic syndrome (MS) and appear to have lower inflammation levels compared to MUO. This study aimed to investigate the association of obesity phenotypes with leptin (LEP) and adiponectin (ADP). According to the inclusion and exclusion criteria, we selected 178 subjects from the previous cross-sectional survey. Based on the body mass index (BMI) and diagnostic criteria of MS, we divided the individuals into three groups, including healthy control group (HC group), metabolically healthy obesity group (MHO group) and metabolically unhealthy obesity group (MUO group). The concentrations of LEP and ADP in serum were measured, and the association of these two cytokines with different obesity phenotypes were subsequently analyzed. Compared to both the HC and MHO groups, the MUO group showed significantly higher BMI, waist circumference (WC), waist-hip ratio (WHR), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), fasting plasma glucose (FPG), homeostasis model assessment of insulin resistance (Homa-IR) and blood pressure (P < 0.05). In contrast, serum high-density lipoprotein cholesterol (HDL-C) was notably lower in the MUO group (P < 0.05). ADP was found to have a positive correlation with systolic blood pressure (SBP) and a negative correlation with FPG in the MHO group. In the MUO group, LEP demonstrated a positive correlation with fasting insulin (FINS) and Homa-IR, while ADP showed a positive correlation with TC and SBP. Linear regression analysis further indicated that SBP (β = 0.234, P = 0.043), TG (β = - 0.292, P = 0.001) and LDL-C (β = 0.626, P = 0.000) were independently correlated with ADP, and BMI (β = 0.398, P = 0.002) was independently correlated with LEP in obese individuals. In conclusion, ADP and LEP were closely related with glucose and lipid metabolism in obese individuals, these two cytokines might play critical roles in obesity-associated metabolic disorders.
Identifiants
pubmed: 37853077
doi: 10.1038/s41598-023-43550-8
pii: 10.1038/s41598-023-43550-8
pmc: PMC10584881
doi:
Substances chimiques
Adiponectin
0
Cholesterol, LDL
0
Cytokines
0
Leptin
0
Triglycerides
0
ADIPOQ protein, human
0
LEP protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17718Informations de copyright
© 2023. Springer Nature Limited.
Références
Curr Opin Lipidol. 2007 Jun;18(3):263-70
pubmed: 17495599
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Lancet Diabetes Endocrinol. 2013 Oct;1(2):152-62
pubmed: 24622321
Endocrine. 2021 Sep;73(3):580-587
pubmed: 34023981
Regul Pept. 2008 Aug 7;149(1-3):26-31
pubmed: 18453013
Endocr Rev. 2020 May 1;41(3):
pubmed: 32128581
Life (Basel). 2021 Dec 07;11(12):
pubmed: 34947881
Endocrinology. 1998 Feb;139(2):551-8
pubmed: 9449624
J Clin Invest. 2019 Oct 1;129(10):3978-3989
pubmed: 31524630
Curr Opin Lipidol. 2010 Feb;21(1):38-43
pubmed: 19915462
Nutrients. 2016 Jun 01;8(6):
pubmed: 27258304
Nature. 2006 Dec 14;444(7121):860-7
pubmed: 17167474
Int J Clin Pract. 2021 Nov;75(11):e14727
pubmed: 34383387
Int J Med Sci. 2016 Jan 01;13(1):25-38
pubmed: 26816492
Trends Pharmacol Sci. 2015 Jul;36(7):461-70
pubmed: 26022934
Nat Rev Endocrinol. 2013 Jan;9(1):13-27
pubmed: 23165161
J Hypertens. 2009 Jul;27(7):1370-6
pubmed: 19412132
Diabetes Care. 2006 Jun;29(6):1357-62
pubmed: 16732021
Iran J Public Health. 2019 Jun;48(6):1106-1115
pubmed: 31341853
Exp Ther Med. 2019 Jan;17(1):791-797
pubmed: 30651864
Lancet. 2011 Feb 12;377(9765):557-67
pubmed: 21295846
Metabolism. 2010 Mar;59(3):424-9
pubmed: 19846168
Obes Rev. 2014 Jun;15(6):504-15
pubmed: 24661566
Mediators Inflamm. 2012;2012:456456
pubmed: 23091306
J Obes. 2015;2015:178526
pubmed: 25838943
Annu Rev Immunol. 2011;29:415-45
pubmed: 21219177
J Clin Endocrinol Metab. 2004 Jun;89(6):2665-71
pubmed: 15181039
Appetite. 2017 Jan 1;108:477-482
pubmed: 27838444
Metabolism. 2015 Jan;64(1):24-34
pubmed: 25199978
J Clin Endocrinol Metab. 2015 Nov;100(11):4172-80
pubmed: 26401592
Eur J Endocrinol. 2006 Jul;155(1):167-76
pubmed: 16793964
Metabolism. 2019 Mar;92:51-60
pubmed: 30458177
J Obstet Gynaecol. 2012 Jan;32(1):73-7
pubmed: 22185543
Rev Endocr Metab Disord. 2013 Sep;14(3):219-27
pubmed: 23928851
Curr Pharm Des. 2014;20(4):652-8
pubmed: 23688014
Diabetes Metab Syndr Obes. 2020 Aug 26;13:3099-3112
pubmed: 32904655
Exp Ther Med. 2014 Apr;7(4):1023-1027
pubmed: 24669271
N Engl J Med. 2008 Nov 13;359(20):2105-20
pubmed: 19005195
Rev Diabet Stud. 2019;15:83-94
pubmed: 31904760
Circ J. 2004 Nov;68(11):975-81
pubmed: 15502375